Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Total Current Liabilities (2020 - 2024)

Immuneering has reported Total Current Liabilities over the past 5 years, most recently at $6.9 million for Q3 2024.

  • Quarterly results put Total Current Liabilities at $6.9 million for Q3 2024, up 23.08% from a year ago — trailing twelve months through Sep 2024 was $6.9 million (up 23.08% YoY), and the annual figure for FY2023 was $7.8 million, down 2.59%.
  • Total Current Liabilities for Q3 2024 was $6.9 million at Immuneering, up from $6.8 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for IMRX hit a ceiling of $8.1 million in Q4 2022 and a floor of $2.3 million in Q4 2020.
  • Median Total Current Liabilities over the past 5 years was $5.5 million (2023), compared with a mean of $5.6 million.
  • Biggest five-year swings in Total Current Liabilities: surged 149.74% in 2021 and later dropped 22.51% in 2023.
  • Immuneering's Total Current Liabilities stood at $2.3 million in 2020, then skyrocketed by 149.74% to $5.6 million in 2021, then surged by 42.96% to $8.1 million in 2022, then fell by 2.59% to $7.8 million in 2023, then fell by 11.8% to $6.9 million in 2024.
  • The last three reported values for Total Current Liabilities were $6.9 million (Q3 2024), $6.8 million (Q2 2024), and $5.2 million (Q1 2024) per Business Quant data.